Affymax has received a $50 million development milestone payment from Takeda Pharmaceutical Co., triggered by the FDA approval of Omontys (peginesatide) Injection. Affymax also received a $5 million milestone payment triggered by the EMA acceptance of the MAA back in February.

In 2006, the companies entered an exclusive global agreement to develop and commercialize Omontys Injection. Both companies are working together to commercialize Omontys in the U.S. Takeda holds an exclusive license to develop and commercialize the product outside the U.S.